Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lipoma16.18.01.001; 15.09.01.0010.000313%Not Available
Listless19.04.04.003; 08.01.01.0120.000313%Not Available
Liver disorder09.01.08.0010.001253%Not Available
Lung consolidation22.01.02.0100.000470%Not Available
Lung disorder22.02.07.0010.000940%Not Available
Lung infiltration22.01.02.0040.001567%Not Available
Lymphadenitis01.09.01.0010.000313%Not Available
Lymphadenopathy01.09.01.0020.003885%Not Available
Lymphoma16.20.01.001; 01.12.01.0010.002506%Not Available
Lymphopenia01.02.02.0020.003603%Not Available
Macrocytosis01.07.02.0030.000313%Not Available
Macular degeneration06.09.03.001--Not Available
Malaise08.01.01.0030.010590%
Malignant melanoma23.08.01.001; 16.03.01.0010.001567%Not Available
Mass08.03.05.0030.000627%Not Available
Mediastinum neoplasm22.09.03.003; 16.19.07.0010.000313%Not Available
Melanocytic naevus23.10.01.007; 16.26.01.0070.000470%Not Available
Meningitis17.06.03.001; 11.01.03.001--
Metastatic malignant melanoma23.08.01.002; 16.03.01.0020.000940%Not Available
Mouth ulceration07.05.06.0040.001786%Not Available
Mucosal ulceration08.01.06.0030.000627%Not Available
Mucous stools07.01.03.0060.000313%Not Available
Multiple sclerosis17.16.01.001; 10.04.10.0080.000627%Not Available
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.001880%
Musculoskeletal pain15.03.04.0070.001629%
Mutism19.19.01.001; 17.02.08.007--Not Available
Myalgia15.05.02.0010.003133%
Myasthenia gravis17.05.04.001; 15.05.08.001; 10.04.05.001--
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene